Gilead Sciences (NASDAQ:GILD) CFO Sells $372,930.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded up $3.65 during mid-day trading on Friday, reaching $124.91. The stock had a trading volume of 10,638,850 shares, compared to its average volume of 6,570,563. The business’s 50 day moving average price is $123.24 and its 200 day moving average price is $117.92. Gilead Sciences, Inc. has a 1 year low of $91.68 and a 1 year high of $128.70. The company has a market cap of $154.97 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 0.65 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the company earned $2.02 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Citigroup boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday. Wolfe Research reaffirmed an “outperform” rating and set a $150.00 target price on shares of Gilead Sciences in a report on Monday, December 15th. Mizuho boosted their price target on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Finally, Royal Bank Of Canada lowered their price objective on Gilead Sciences from $105.00 to $100.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.16.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in Gilead Sciences during the second quarter worth $2,150,268,000. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the period. Invesco Ltd. raised its holdings in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after buying an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Gilead Sciences during the second quarter worth approximately $238,083,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.